arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Sionna Therapeutics, Inc.

SION

$51.03 ▲ +1.48 (+2.99%) at close

10 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Bearish

auto_awesome

Analytical Summary

Sionna Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.3B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -8.1% ↘

FCF / Share $-0.49

Trailing P/E —

Price / Book 8.0x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-26.78M

↓ -62.5% —

FCF / Share Free cash flow per share

$-0.49

↑ +21.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
EPS Growth YoY (%)	99.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	85.8% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	91.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	84.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	83.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	-62.5% Weak ↓ Weak Declining Year-over-year change in net income	-29.0% Weak ↑ Weak Improving Year-over-year change in net income	-39.1% Weak → Weak Stable Year-over-year change in net income	-39.1% Weak Weak Year-over-year change in net income	-39.1% Weak Weak Year-over-year change in net income	—	—	—	—	—
FCF Growth YoY (%)	21.0% Good ↓ Good Declining Year-over-year change in free cash flow	—	91.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	87.2% Excellent Excellent Year-over-year change in free cash flow	85.6% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
FCF / Net Income (x)	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	1.10x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	0.99x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.49x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.11x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Return on Invested Capital (%)	-8.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-5.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-5.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-4.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	8.8% Fair ↓ Fair Declining Return earned on debt + equity capital invested Optimal: > 10%	14.9% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	6.7% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	8.2% Fair Fair Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-9.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-7.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-7.0% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-6.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-5.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-9.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-9.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-162%)	-6.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-144%)	-5.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-134%)	-4.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-133%)	-4.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-131%)	9.7% Caution ↑ Caution Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-35%)	8.0% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-47%)	8.9% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-41%)	9.4% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-37%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Net Debt (USD)	$-63.32M	$-58.45M	$-50.83M	$-40.98M	$-82.69M	$-37.79M	$-35.75M	$-44.02M	$-82.75M	—

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Basic EPS, GAAP (USD)	$-0.60	$-0.45	$-0.46	$-410.00	$-620.00	$-3.18	$-5.67	$-2.71K	$-3.84K	—
Free Cash Flow per Share (USD)	$-0.49	—	$-0.35	$-0.41	$-0.62	—	$-3.94	$-3.21	$-4.27	—
Book Value per Share (USD)	$6.39	$6.86	$7.23	$7.62	$7.98	$-34.66	$-33.12	$-42.34	$-40.90	—
Tangible Book Value per Share (USD)	$6.39	$6.86	$7.23	$7.62	$7.98	$-34.66	$-33.12	$-42.34	$-40.90	—
Basic Weighted Avg Shares (shares)	44.92M	—	44.26M	44.12M	26.60M	—	4.49M	3.16M	3.08M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Working Capital (USD)	$211.18M	$229.71M	$242.48M	$259.20M	$264.15M	$140.57M	—	—	—	—
Total Equity (USD)	$288.21M	$306.83M	$321.67M	$336.43M	$351.77M	$-163.71M	$-148.55M	$-133.77M	$-126.08M	$-114.88M

📋 What is driving earnings? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Depreciation Expense (USD)	$154.00K	$152.00K	$100.00K	$100.00K	$159.00K	$167.00K	$200.00K	$200.00K	$166.00K	—
Net Income, GAAP (USD)	$-26.78M	$-20.44M	$-16.48M	$-16.48M	$-16.48M	$-15.85M	$-11.85M	$-11.85M	$-11.85M	—
Operating Cash Flow (USD)	$-21.84M	$-16.63M	$-15.23M	$-18.15M	$-16.29M	$-11.78M	$-17.69M	$-10.14M	$-13.18M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 3 years · 10 quarters

Sionna Therapeutics, Inc.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare SION with peers